Ginkgo Bioworks Holdings, Inc. (DNA) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 5 Buy, 2 Hold, 4 Sell.
The consensus price target is $7.84 (low: $4.35, high: $12.00), representing an upside of 1.6% from the current price $7.72.
Analysts estimate Earnings Per Share (EPS) of $-10.08 and revenue of $0.23B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-10.54 vs est $-10.08 (missed -4.6%). 2025: actual $-5.64 vs est $-5.64 (beat +0%). Analyst accuracy: 98%.
DNA Stock — 12-Month Price Forecast
$7.84
▲ +1.55% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Ginkgo Bioworks Holdings, Inc., the average price target is $7.84, with a high forecast of $12.00, and a low forecast of $4.35.
The average price target represents a +1.55% change from the last price of $7.72.
Highest Price Target
$12.00
Average Price Target
$7.84
Lowest Price Target
$4.35
DNA Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to Ginkgo Bioworks Holdings, Inc. in the past 3 months
EPS Estimates — DNA
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$10.54
vs Est –$10.08
▼ 4.4% off
2025
Actual –$5.64
vs Est –$5.64
▼ 0.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — DNA
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.227B
vs Est $0.228B
▼ 0.3% off
2025
Actual $0.170B
vs Est $0.174B
▼ 2.2% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
